Objective:To explore the difference between the prevalence of metabolic syndrome (MetS) and its influencing factors between rheumatoid arthritis (RA) patients and osteoarthritis (OA) patients.Methods:2 024 patients with RA were selected as the experimental group inthe First Central Hospital of Tianjin from January 1, 2014 to March 12, 2019. A total of 1 271 patients with OA who were treated at the same time served as the control group.Relevant indicators were measured, and correlation analysis was performed using logistic regression.Results:The prevalence of MetS in the past six years did not differ significantly inpatients with RA ( χ2=5.77, P=0.06) and OA ( χ2=1.11, P=0.57). MetS risk factors were more prevalent inpatients with OA, and the prevalence of MetS in patients with OA was also higher than patients with RA ( χ2=19.07, P<0.01). In logistic regression model, the prevalence of MetS was positively correlated with body weight {RA: 1.14[(95% CI(1.10, 1.18), P<0.01]; OA: 1.11[95% CI(1.07, 1.16), P<0.01]}, blood levels of triglyceride {RA:2.64[95% CI(1.58, 4.40), P<0.01] and OA: 2.91[95% CI(1.32, 6.43), P=0.01]}, and glucose {RA:1.67[95% CI(1.42, 1.97), P<0.01] and OA: 1.76[95% CI(1.31, 2.35), P<0.01]}, and negatively correlated with blood level of high-density lipoprotein cholesterol{RA: 0.09[95% CI(0.02, 0.32), P<0.01] and OA: 0.03[95% CI(0.01, 0.25), P<0.01]} in patients with RA and OA. MetS risk factors such as serum creatinine (Scr) only presented in RA patients 1.04 [ OR: 95% CI(1.01, 1.06), P<0.01]. Conclusion:The prevalence of MetS did not decrease in patients with chronic inflammatory arthritis in the past six years, and OA patients havea greater risk of MetS.

Objective:To examine the associations between serum magnesium (Mg) concentration and metabolic syndrome (MetS), diabetes (DM), hypertension (HTN), hyperuricemia (HU) in rheumatoid arthritis (RA) patients.Methods:From June 29, 2013 to February 29, 2019, 1 009 RA patients were collected at Tianjin First Central Hospital. The Mg concentration, clinical and laboratory indicators, living habits and medication were collected. The multivariate adjusted Logistic regression model was used to evaluate the relationship between Mg and MetS, DM, HTN, and HU.Results:Compared with the lowest quintile serum magnesium, In the MetS regression analysis, OR and 95% CI were 0.26 [95% CI(0.09, 0.76), P=0.01)], 0.17 [95% CI (0.06, 0.47), P<0.01], 0.27 [95% CI(0.09, 0.76), CI=0.01], and 0.22 [95% CI(0.09, 0.58), P<0.01], in second, third, fourth, and fifth (highest) quantiles of serum Mg, respectively, P for trend <0.01. In DM regression analysis, after adjusting for multiple potential confounders in Model 2, OR and 95% CI were 0.58 [95% CI (0.35, 0.96), P=0.03], and 0.51 [95% CI (0.29, 0.89), P=0.02], in third and fifth quantiles of the serum Mg, respectively, P for trend =0.01. But in model 3 this correlation disappears. HTN and HU were not associated with serum Mg ( P>0.05), P for trend >0.05. Conclusion:There was a negative correlation between serum Mg concentration and MetS in RA patients, But no correlation with HTN, HU. After adjusting the glomerular filtration rate, the negative correlation between serum Mg and DM also disappeared.

0 05].The sensitivities in pSS patients with lower lip biopsy and in pSS patients without lower lip biopsy were 88 3% and 84 6% respectively.The total sensitivity was 87 0% and the specificity was 97 8%.At least 11 2% of pSS patients with negative anti SSA/SSB antibodies were diagnosed by lower lip biopsy.Conclusion The new international classification criteria for pSS are feasible in Chinese patients.It has a high sensitivity of 87 0% and a high specificity of 97 8% which may serve as diagnosis criteria in routine clinical practice

In recent years, with the continuous in-depth research on the pathogenesis of rheumatism and the rapid development of biopharmaceutical technology, the development of targeted drugs for rheumatism is in full swing. In order to better standardize the diagnosis and treatment of rheumatism and the rational application of targeted drugs, the Chinese Rheumatology Association will introduce the targeted drugs for rheumatism that have been approved by the China National Medical Products Administration so far, and provide clinicians with standardized diagnosis and treatment reference.